Lutikizumab Meets Phase 3 Response Endpoint in Hidradenitis

Company AbbVie Event Type Phase 3 topline readout Modality Dual IL-1α/IL-1β antibody (dual-variable-domain) Asset Lutikizumab Target IL-1α and IL-1β Disease Area Hidradenitis suppurativa Summary INTREPID establishes a statistically significant Phase 3 signal for dual IL-1α and IL-1β inhibition in hidradenitis suppurativa, with an eight-point absolute…